Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

  • End date
    Jun 30, 2023
  • participants needed
  • sponsor
Updated on 27 April 2022


A study to evaluate posoleucel (ALVR105); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.


The study hypothesis is that the administration of posoleucel (ALVR105) to patients with virus-associated HC will demonstrate superiority for the time to resolution of HC (as measured by resolution of macroscopic hematuria) compared to patients treated with placebo. The primary hypothesis will be tested in patients with BK virus (BKV) viruria to demonstrate superiority over placebo in this population (BK Intent-to-Treat [ITT] Population). A supplementary analysis will be conducted in all patients with any virus-associated HC (cytomegalovirus [CMV], human herpesvirus 6 [HHV-6], Epstein-Barr virus [EBV], JC virus [JCV], and/or adenovirus [AdV]) in order to evaluate efficacy in this broader population (ITT Population).

Condition BK Virus Infection, Hemorrhagic Cystitis
Treatment Placebo, Viralym-M, ALVR105 (Viralym-M), Posoleucel (ALVR105)
Clinical Study IdentifierNCT04390113
Last Modified on27 April 2022


Yes No Not Sure

Inclusion Criteria

Participants must meet all of the following criteria in order to be eligible to participate
in the study
Diagnosed with HC based on the following criteria (all 3 criteria must be met)
Male or female ≥1 year of age
Had an allogeneic hematopoietic cell transplant (HCT) performed ≥21 days and ≤1 year
prior to randomization
Myeloid engraftment confirmed, defined as an absolute neutrophil count ≥500/mm³ for 3
consecutive laboratory values obtained on different days, and platelet count
>10,000/mm³ at the time of randomization
Clinical signs and/or symptoms of cystitis
Viruria with ≥1 target virus (ie, BKV, JCV, AdV, CMV, EBV, and/or HHV-6)
Grade ≥3 hematuria, defined as macroscopic hematuria with visible clots
At least 1 identified, suitably matched posoleucel (ALVR105) cell line for infusion is

Exclusion Criteria

Evidence of active Grade >2 acute graft versus host disease (GVHD)
Pregnant or lactating or planning to become pregnant
Uncontrolled or progressive bacterial or fungal infections
Participants who meet any of the following criteria will be excluded from participation in
the study
Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose >0.5
mg/kg/day or equivalent)
immunosuppressive T cell-targeted monoclonal antibodies ≤28 days before randomization
Therapy with antithymocyte globulin, alemtuzumab (Campath-1H), or other
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Uncontrolled or progressive viral infections not targeted by posoleucel (ALVR105)
Uncontrolled or progressive EBV-associated post-transplant lymphoproliferative
Known or presumed pneumonia secondary to any organism that is not considered to be
well-controlled by antimicrobial therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note